Medigene AG: Medigene collaborates with RXi Pharmaceuticals to further sharpen its therapeutic T cells
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
- Synergies between the recombinant T cell technologies of Medigene and self-delivering RNAi technologies from RXi Pharm…
Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announces that a scientific article on a method to identify T cell…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), will demonstrate the use of its automated high-throughput screening (HT…
- Automated in vitro testing could reveal better neoantigens that activate more effective killer T cell responses - Two…
. - First poster reports of a semi-automated method for the isolation and initial characterization of neoantigen-specif…
Article in "Cancer Research" published in collaboration with scientists from nine academic research groups in Berlin, Mu…
. - T-cell receptor (TCR) T4.8-1-29 isolated from healthy blood donor - Natural high avidity and favorable preclinical…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX) announced that researchers from Oslo University Hospital presented an up…
Medigene AG (FSE: MDG1, Prime Standard, TecDAX), today announced details on the Company's first clinical trial with T-ce…
Prof. Dolores Schendel, CEO and CSO of Medigene AG (MDG1, Frankfurt, Prime Standard), will present a new approach to dev…